

IMPORTANT SAFETY INFORMATION

24 June 2013

Restrictions for use of Trobalt® (retigabine) - treatment may lead to pigment changes of ocular tissues, including retina, and skin, lips and/or nails

**GlaxoSmithKline
Pharmaceuticals**
Stonemasons Way
Rathfarnham
Dublin 16
Ireland

Tel. +353-1-495 5000
Fax. +353-1-495 5105
www.gsk.ie

Dear Healthcare Professional

In agreement with the Committee for Medicinal Products for Human Use (CHMP) and the Irish Medicines Board (IMB), GlaxoSmithKline (GSK) would like to inform you of a restriction of the indication for Trobalt® (retigabine) following reports of pigment changes and provide you with recommendations for monitoring.

Summary

- Trobalt® should now only be used as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
- Pigment changes (discolouration) of ocular tissue, including the retina, have been reported in long-term clinical studies with retigabine.
- Blue-grey discolouration of the nails, lips and/or skin have also been observed in these studies.
- Patients currently receiving treatment should be reviewed at a routine (non-urgent) appointment. The balance of benefits and risks should be re-evaluated, and patients should be informed of the risk of pigmentation with long term treatment.
- A comprehensive ophthalmological examination (including visual acuity test, slit-lamp examination, and dilated funduscopy) should be performed at treatment start and at least every 6 months thereafter while treatment is ongoing. Patients already treated with retigabine should have an appointment scheduled for an ophthalmological examination.
- If retinal pigment or vision changes are detected, treatment with Trobalt should only be continued after a careful re-assessment of the balance of benefits and risks. Also in patients who develop discolouration of the nails, lips or skin, treatment with Trobalt should only be continued after a careful re-assessment of the balance of benefits and risks.

Further information on the safety concern

Trobalt® (retigabine) is now indicated as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.

Among the patients treated with retigabine in two long-term clinical studies and the associated compassionate use programme, eye examinations in 55 patients were completed up to 2 May 2013. Baseline eye assessments were not performed in these studies. Twenty-one cases of pigment changes (discolouration) of ocular tissue, including 15 involving the retina have been reported. Five patients had worse than 20/20 visual acuity. One of these patients had visual acuity of 20/160 in one eye, while the remaining four had visual acuity of 20/25 to 20/40 in one or both eyes.

Mild abnormalities on retinal electrophysiology tests have been reported in two further subjects, both of whom had visual acuity reported to be normal. In one of those subjects, a generalised reduction in the visual fields of both eyes on Humphrey Visual Testing was also noted.

Up to 2 May 2013, 51 cases with events relating to discolouration/ pigmentation of the nails, lips and/or skin after treatment with retigabine were received from the two long-term clinical studies and the compassionate use programme. The events generally presented after long-term exposure to retigabine, with a median time to onset of 4.4 years (range 4 months to 6.7 years) (time to onset refers to date discolouration events were first reported; in some cases the patient is described as having the event(s) before mentioning them to the investigator). There appeared to be no relation with age or gender. Events tended to occur at higher doses, usually 900 mg/day or higher.

The changes described above have been observed in a high proportion of patients who were still ongoing in the long-term studies. About one third of the patients examined so far have presented with retinal pigment changes. The cause, natural history and long-term prognosis of the changes are currently unknown, and further investigative work is ongoing.

Reports of pigmentation/discolouration are considered to be very common adverse events ($\geq 1/10$) following prolonged treatment with retigabine.

The Summary of Product Characteristics and Package Leaflet are being revised to include information on the amended indication and these safety risks.

Call for reporting

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

In the case of suspected adverse reactions you can report to: GlaxoSmithKline (Ireland) Ltd., Stonemasons Way, Rathfarnham, Dublin 16 (Freephone 1800 244 255, Fax 01 4938839 or e-mail ireland.drugsurveillance@gsk.com)

Healthcare professionals should continue to report suspected adverse reactions to the IMB using a Yellow Card obtained either from the IMB, or electronically via the website at www.imb.ie. Adverse reactions can also be reported to the IMB by calling (01) 676 4971.

Communication Information

Should you have any questions or require additional information please contact GlaxoSmithKline (Ireland) Ltd., Stonemasons Way, Rathfarnham, Dublin 16 (Freephone 1800 244 255).

The information contained in this letter has been endorsed by the European Medicines Agency and national Competent Authorities.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'S. McDonough', with a stylized flourish at the end.

Dr Stephen McDonough BM BS MSc MRCGP FFPM

Medical Director Ireland and Associate Medical Director UK

GlaxoSmithKline UK, Stockley Park West, Uxbridge UB11 1BT, United Kingdom

GlaxoSmithKline Ireland, Stonemasons Way, Rathfarnham, Dublin 16, Ireland